Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million

Reuters

03/27

Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million

iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.
Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.
Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.
Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.
Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2622466896"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622466896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622466896?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 04:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622466896","market":"fut","top_or_hot":-1,"title":"Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        </li>\n<li>\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        </li>\n<li>\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        </li>\n<li>\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        </li>\n<li>\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IMDX\">Insight Molecular Diagnostics Inc.</a> published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 04:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        </li>\n<li>\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        </li>\n<li>\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        </li>\n<li>\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        </li>\n<li>\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IMDX\">Insight Molecular Diagnostics Inc.</a> published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDIT","symbol_name":"Medite Cancer Diagnostics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL7Y4TcY:1","article_id":"2622466896","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622466896","pubTimestamp":1774555787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDIT":"Medite Cancer Diagnostics, Inc.","BK4082":"医疗保健设备","BK4139":"生物科技","IMDX":"Insight Molecular Diagnostics Inc."},"translate_title":"Insight Molecular Diagnostics 2025财年收入增长115.79%至410万美元；运营费用攀升37%至5,340万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMDX":0.9,"MDIT":0.9},"content_text":"Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    \n\n\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        \n\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        \n\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        \n\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        \n\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}